Amgen (NASDAQ:AMGN) Versus Axcella Health (NASDAQ:AXLA) Head-To-Head Contrast
Amgen (NASDAQ:AMGN) Versus Axcella Health (NASDAQ:AXLA) Head-To-Head Contrast
Axcella Health (NASDAQ:AXLA – Get Rating) and Amgen (NASDAQ:AMGN – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.
安賽樂健康(納斯達克：AXLA-GET評級)和安進(納斯達克：AMGN-GET評級)都是醫療公司，但哪隻股票更優越？我們將根據兩家公司的股息實力、估值、分析師建議、風險、機構所有權、收益和盈利能力對它們進行比較。
Valuation & Earnings
估值與收益
This table compares Axcella Health and Amgen's gross revenue, earnings per share (EPS) and valuation.
此表比較了Axcell a Health和安進的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Axcella Health | N/A | N/A | -$64.63 million | ($1.66) | -0.38 |
| Amgen | $25.98 billion | 5.27 | $5.89 billion | $12.47 | 20.57 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| AXCELA健康 | 不適用 | 不適用 | -6,463萬元 | ($1.66) | -0.38 |
| 安進 | 259.8億美元 | 5.27 | 58.9億美元 | $12.47 | 20.57 |
Amgen has higher revenue and earnings than Axcella Health. Axcella Health is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
安進的收入和收益比Axcell a Health更高。Axcell a Health的市盈率低於安進，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Ratings
分析師評級
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Axcella Health | 0 | 2 | 2 | 0 | 2.50 |
| Amgen | 4 | 4 | 4 | 0 | 2.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| AXCELA健康 | 0 | 2 | 2 | 0 | 2.50 |
| 安進 | 4 | 4 | 4 | 0 | 2.00 |
Axcella Health presently has a consensus price target of $5.25, suggesting a potential upside of 733.33%. Amgen has a consensus price target of $253.57, suggesting a potential downside of 1.16%. Given Axcella Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Axcella Health is more favorable than Amgen.
Axcell a Health目前的共識目標價為5.25美元，這意味着潛在的上漲幅度為733.33。安進的普遍目標價為253.57美元，這意味着潛在的下跌幅度為1.16%。考慮到Axcell a Health更強勁的共識評級和更高的可能上行空間，股票研究分析師顯然認為Axcell a Health比Amgen更有利。
Volatility and Risk
波動性和風險
Axcella Health has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Axcell a Health的貝塔係數為1.19，表明其股價的波動性比標準普爾500指數高出19%。相比之下，安進的貝塔係數為0.67，這表明其股價的波動性比標準普爾500指數低33%。
Profitability
盈利能力
This table compares Axcella Health and Amgen's net margins, return on equity and return on assets.
此表比較了Axcell a Health和安進的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Axcella Health | N/A | -567.25% | -147.10% |
| Amgen | 25.96% | 287.23% | 16.16% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| AXCELA健康 | 不適用 | -567.25% | -147.10% |
| 安進 | 25.96% | 287.23% | 16.16% |
Insider and Institutional Ownership
內部人與機構持股
71.1% of Axcella Health shares are owned by institutional investors. Comparatively, 75.5% of Amgen shares are owned by institutional investors. 6.5% of Axcella Health shares are owned by company insiders. Comparatively, 0.5% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Axcella Health 71.1%的股份由機構投資者持有。相比之下，安進75.5%的股份由機構投資者持有。Axcell a Health 6.5%的股份由公司內部人士持有。相比之下，安進0.5%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一隻股票有望實現長期增長。
Summary
摘要
Amgen beats Axcella Health on 9 of the 13 factors compared between the two stocks.
安進在比較兩隻股票的13個因素中有9個超過了Axcella Health。
About Axcella Health
關於Axcella Health
(Get Rating)
(獲取評級)
Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
Axcell a Health，Inc.是一家生物技術公司。它從事疾病治療的研究和開發，並使用內源性代謝調節劑或EMM及其組合物改善健康。其產品線包括用於降低復發臨牀肝性腦病風險的AXA1665和用於非酒精性脂肪性肝炎的AXA1125。該公司由Noubar B.Afeyan、Geoffrey von Maltzahn和David A.Berry於2008年8月27日創立，總部設在馬薩諸塞州劍橋市。
About Amgen
關於安進
(Get Rating)
(獲取評級)
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
安進公司是一家生物技術公司，從事人類療法的發現、開發、製造和營銷。其產品包括以下品牌：Aranesp、Aimovig、Kanjinti、EVENITY、AMGEVITA、AVSOLA、BLINCETO、MVASI、Corlanor、Enbrel、Epogen、Imlyic、Kyprolis、Neulasta、NEUPOGEN、NPLATE、Parsabiv、Prolia、Repatha、Sensiar、Vectibix、Otezla、RIABNI和XGEVA。該公司由小威廉·K·鮑斯、小富蘭克林投手約翰遜、喬治·B·拉特曼和約瑟夫·魯賓菲爾德於1980年4月8日創立，總部設在加利福尼亞州千橡市。
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Axcell健康日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Axcella Health和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。